Vir Biotechnology Inc
Change company Symbol lookup
Select an option...
VIR Vir Biotechnology Inc
$NQUSB40401010N Nasdaq US Benchmark Diversified Reta
IVZ Invesco Ltd
SPLK Splunk Inc
TW Tradeweb Markets Inc
CMPGY Compass Group PLC
FCPT Four Corners Property Trust Inc
BMI Badger Meter Inc

Health Care : Biotechnology | Small Cap Growth
Company profile

Vir Biotechnology, Inc. is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. It has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The Company's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. It is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.


Last Trade
-0.16 (-0.53%)
B/A Size

Market Hours

Closing Price
Day's Change
0.23 (0.77%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

EBay stock jumps after earnings beat, in-line holiday forecast

8:15 am ET November 3, 2022 (MarketWatch)

By Jeremy C. Owens and Wallace Witkowski

Revenue declines, but was above Wall Street expectations

EBay Inc. shares jumped more than 6% in premarket trading Thursday, after the online marketplace beat expectations for earnings and revenue and predicted an in-line holiday quarter.

EBay (EBAY) reported late Wednesday a third-quarter net loss of $70 million, or 13 cents a share, compared with earnings of 43 cents a share in the year-ago period. Adjusted earnings, which exclude stock-based compensation expenses and other items, were $1 a share, compared with 90 cents a share in the year-ago period.

Revenue declined to $2.38 billion from $2.5 billion in the year-ago quarter. Analysts surveyed by FactSet had forecast adjusted earnings of 93 cents a share on revenue of $2.32 billion. After closing with a 4.4% decline at $38.06, shares were trading for close to $41 in the extended session Wednesday.

"I'm proud of our team and community for remaining resilient in the face of a challenging macroeconomic environment," Chief Executive Jamie Iannone said in a statement.

Macroeconomic concerns have weighed on eBay, as pandemic gains for e-commerce companies come back to earth and rising inflation puts a crimp in consumers' budgets. The stock has fallen 42.5% in the past year, while the S&P 500 index has dropped 19.1%, and that spread has widened in the past three months, with eBay shares falling 21.2% and the S&P declining 5.8%.

"Macro headwinds such as record-high [inflation], rising interest rates, supply chain disruptions, geopolitical conflict, and adverse [foreign exchange] have all seemingly worsened since the [previous earnings report], continuing to weigh on discretionary spend levels and broader e-commerce," JP Morgan analyst Doug Anmuth wrote Monday, while reducing his price target on the stock to $43 from $50 and maintaining a neutral rating.

"Some may view eBay as defensive/value-oriented given the majority of GMV is preowned (Non-New In-Season), but we generally view most items and the focus categories it has leaned into (i.e. luxury watches, designer handbags, sneakers, & trading cards) as discretionary in nature and believe they could be challenged in a recessionary environment," he continued.

EBay forecast adjusted earnings of $1.03 to $1.09 a share on revenue of $2.42 billion to $2.5 billion for the fourth quarter. Analysts had estimated $1.05 a share on revenue of $2.49 billion for the fourth quarter, according to FactSet.

-Jeremy C. Owens


(END) Dow Jones Newswires

November 03, 2022 08:15 ET (12:15 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.